Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer
Cancer · 2026
DOI: 10.1002/cncr.70294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Maria J Monroy-Iglesias und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Drug Tapering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Geoffrey Beene Cancer Research Center, National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
For most cytotoxic drugs, guidelines recommend body‐surface‐area–based dosing, yet some patients start with reduced doses, potentially reflecting tolerability concerns. The relationship between first‐cycle dose reductions and subsequent delivery is unclear.
Methods
The authors analyzed data from women with stage I–IIIA breast cancer treated with adjuvant chemotherapy. Sankey diagrams illustrated trajectories from first‐cycle dose proportion (FCDP) to average relative dose intensity (ARDI, ratio of received to expected dose intensity across the regimen), and cumulative dose proportion (CDP, ratio of total received to expected dose). Poisson regression estimated adjusted prevalence ratios for reduced FCDP (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
- Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
- Division of Hematology/Oncology, Department of Medicine, Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Oncology, Kaiser Permanente Medical Center, Vallejo, California, USA.
ORCID-Profile: Maria J Monroy-Iglesias, Isaac J Ergas, Grace B Gallagher, Candyce H Kroenke, Yashasvini Sampathkumar, Erin J Aiello Bowles, Elizabeth D Kantor
Förderung
- NCI NIH HHS
- Geoffrey Beene Cancer Research Center
- National Cancer Institute
Zitieren
APA
Monroy-Iglesias, M. J., O'Connell, K., Bhimani, J., Blinder, V. S., Burganowski-Doud, R. P., Ergas, I. J., Gallagher, G. B., Griggs, J. J., Heon, N., Kolevska, T., Kotsurovskyy, Y., Kroenke, C. H., Laurent, C. A., Liu, R., Nakata, K. G., Persaud, S., Roh, J. M., Sampathkumar, Y., Tabatabai, S., …, & Kantor, E. D. (2026). Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer. Cancer. https://doi.org/10.1002/cncr.70294
Vancouver
Monroy-Iglesias MJ, O'Connell K, Bhimani J, Blinder VS, Burganowski-Doud RP, Ergas IJ, et al. Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer. Cancer. 2026. doi:10.1002/cncr.70294
BibTeX
@article{MonroyIglesias2026,
author = {Monroy-Iglesias, Maria J and O'Connell, Kelli and Bhimani, Jenna and Blinder, Victoria S and Burganowski-Doud, Rachael P and Ergas, Isaac J and Gallagher, Grace B and Griggs, Jennifer J and Heon, Narre and Kolevska, Tatjana and Kotsurovskyy, Yuriy and Kroenke, Candyce H and Laurent, Cecile A and Liu, Raymond and Nakata, Kanichi G and Persaud, Sonia and Roh, Janise M and Sampathkumar, Yashasvini and Tabatabai, Sara and Valice, Emily and Wang, Peng and Aiello Bowles, Erin J and Bandera, Elisa V and Kushi, Lawrence H and Kantor, Elizabeth D},
title = {Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70294}
}
EUVIMED